|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- July 17, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, said partner Boston Scientific Corp., of Natick, Mass., received approval from the FDA to market Taxus Liberte long paclitaxel-eluting coronary stent system designed for long lesions. Clinical studies showed a significant 79 percent reduction in the rate of nine-month myocardial infarction for the Taxus Liberte stent compared to the Taxus Express Stent control (1.3 percent vs. 6.3 percent, p = 0.026). It received CE Mark approval in 2007.
Arrayit Corp., of Sunnyvale, Calif., said it is collaborating with the Parkinson's Institute of Sunnyvale to discover biomarkers for Parkinson's disease. The study ...